Agios Pharma (AGIO) Tops Q1 EPS by 16c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. QGEN
7. CSX
8. LRCX
9. NDAQ
10. BFH

Go back to Agios Pharma (AGIO) Tops Q1 EPS by 16c

Agios Pharma (AGIO) Reports FDA Approval of Supplemental New Drug Application for TIBSOVO

May 2, 2019 1:27 PM EDT

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. Prescribing Information for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor, to include adult patients with newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test who are 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. The sNDA was granted Priority Review and accepted under the FDA's Real-Time Oncology Review pilot program, which aims to make the... More